ERBB2 Antibody

Polyclonal Antibody

ERBB2

Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody, C erb B2/neu protein antibody, CD340 antibody, CD340 antigen antibody, Cerb B2/neu protein antibody, CerbB2 antibody, Erb b2 receptor tyrosine kinase 2 antibody, ErbB-2 proto-oncogene antibody, ERBB2 antibody, ERBB2_HUMAN antibody, HER 2 antibody, HER 2/NEU antibody, HER2 antibody, Herstatin antibody, Human epidermal growth factor receptor 2 antibody, Metastatic lymph node gene 19 protein antibody, MLN 19 antibody, MLN19 antibody, NEU antibody, NEU proto oncogene antibody, Neuro/glioblastoma derived oncogene homolog antibody, Neuroblastoma/glioblastoma derived oncogene homolog antibody, NGL antibody, p185erbB2 antibody, Proto-oncogene c-ErbB-2 antibody, Proto-oncogene Neu antibody, Receptor tyrosine-protein kinase erbB-2 antibody, TKR1 antibody, Tyrosine kinase type cell surface receptor HER2 antibody, Tyrosine kinase-type cell surface receptor HER2 antibody, V erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog) antibody, V erb b2 avian erythroblastic leukemia viral oncogene homolog 2 antibody, V erb b2 avian erythroblastic leukemia viral oncoprotein 2 antibody, V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) antibody, V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody, Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) antibody

A synthetic peptide of human ERBB2

The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity. While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members. Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers. Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase. ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222, phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway.

Affinity-chromatography purified

Tags & Cell Markers

A synthetic peptide of Human ERBB2